Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone H2B type 1-L (H2BC13) is a basic nuclear protein and a core component of the nucleosome, the fundamental unit of chromatin structure in eukaryotic cells[1][2][4][7]. Two molecules each of the four core histones—H2A, H2B (including H2BC13), H3, and H4—form an octamer around which approximately 146 base pairs of DNA are wrapped, enabling compaction and organization of the genome[1][2][4][6][7]. Histone H2B types, including H2BC13, are centrally involved in essential processes such as transcriptional regulation, DNA replication, and DNA repair[1][2][7]. They undergo extensive post-translational modifications (e.g., acetylation, ubiquitination, methylation, phosphorylation) that alter chromatin accessibility and influence gene expression and DNA processing[2][3]. H2BC13, like other replication-dependent histones, is encoded by an intronless gene and produced primarily during the S-phase of the cell cycle. It has a key structural role in nucleosome formation, contributing to chromosomal stability and epigenetic regulation, but is not considered a classical therapeutic target such as a receptor or enzyme[2][4][6]. Disruption of H2B genes or their modifications has been linked to cancer, including hematologic malignancies[1]. No approved drugs are known to selectively target H2BC13 directly, but global histone modifications are targets for certain epigenetic therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone H2B type 1-L (H2BC13).